john hawks weblog

paleoanthropology, genetics and evolution

health

  • Whole genome action

    Thu, 2010-04-29 21:26 -- John Hawks

    Daniel MacArthur writes a thoughtful summary of a new study of the DNA of Stephen Quake: "What can you learn from a whole genome sequence?"

    That means that the real benefit of whole-genome sequencing over other assays - the uncovering of truly novel or rare genetic variants - has much less of an impact than it should, because in most cases it's impossible to assign function to such variants. Indeed, it's striking in this study that the really compelling, actionable findings - the increased risk of myocardial infarction and metabolic diseases, and the drug metabolism effects - come largely from common variants, most of which would be captured by chip-based assays such as that used by 23andMe.

  • Silk electrodes

    Thu, 2010-04-22 19:30 -- John Hawks

    Creepy:

    Silk has made its way from the soft curves of the body to the spongy folds of the brain. Engineers have now designed silk-based electronics that stick to the surface of the brain, similar to the way a silk dress clings to the hips.

  • This weeks' genomes

    Fri, 2010-03-12 19:53 -- John Hawks

    Actress Glenn Close joins the ranks of the genomed; Daniel MacArthur discusses the celebrity genomics trend.

    He covers in greater detail the James Lupski genome story, in which the geneticist sequences his own genome to find out what causes his own genetic disorder, Charcot-Marie-Tooth disease. Beside that success story, he places a second study this week that had a lot more trouble -- a case in which complete genome sequencing of four members of a family could not by itself find the causative variant for two siblings' Miller syndrome.

    The basic problem here is that we're still extremely bad at differentiating between mutations causing serious disease and perfectly benign polymorphisms - each of us have genomes littered with genetic variants that look like nasty mutations but have little or no effect on health. In fact, Lupski's genome illustrates this nicely: one of the mutations causing his disease is a premature stop codon that disrupts the function of a gene - but his genome also contains an additional 120 stop codons disrupting other genes, presumably without severe health effects.

    So all of us are walking around with hundreds of gene-disrupting variants, and finding the single causative gene amongst all that noise is seriously challenging.

    We've been talking about stop codons and pseudogenes a lot here in the Hawks lab this week.

  • Texas newborn DNA experimentation

    Wed, 2010-03-03 00:42 -- John Hawks

    A couple of weeks ago, the Texas Tribune reported on an investigation of the archiving of blood samples taken from newborn infants: "DNA Deception".

    For decades, the state has screened newborns for a variety of birth defects, pricking their heels and collecting five drops of blood on a paper card. Until 2002, the cards were thrown out after a short storage period. But starting that year, the state health department began storing blood spots indefinitely, for “research into causes of selected diseases.” Four years later, DSHS began contracting with Texas A&M University’s School of Rural Public Health to warehouse the cards, which were accumulating at a rate of 800,000 a year. State health officials never notified parents of the changes; they didn’t need consent for the birth-defect screening, so they didn’t ask for it for research purposes. The agency’s rationale was that it let parents who asked opt out of the newborn blood screening and de-identified all of the samples before shipping them off (emphasis added).

    So much for informed consent. "We're from the government, and we're here to help you."

    The state was sued by parents last year and rapidly settled the lawsuit before pre-trial discovery. Now, it is suspected that the state was trying to avoid drawing attention to some of the uses of the blood samples -- including several hundred which were used to develop a forensics database of mtDNA variants.

    E-mails indicate that in 2003, when the agency started to release blood spots for outside research, officials knew they had a parental consent issue on their hands — but tried to avoid it. When a researcher proposed a project, the director of birth defects monitoring wrote that he’d “prefer to not have to go through” the process of getting consent. Another agency official responded that parents "never consented for blood spots to be used for research. … On the other hand, I believe [the health department] already uses (deidentified?) blood spots for some research, so that might not be a big deal.”

    All states now test for metabolic disorders in newborns; the tests require only a blood spot on treated paper. The National Newborn Screening and Genetics Resource Center has more information on the specific tests and a very up-to-date list by state. It is amazing to me, as someone who has had four kids in the last ten years, just how quickly these screening programs became universal.

    It is therefore hard for me to believe that Texas is going to be an exception. Surely we'll discover that some other states are archiving these blood samples instead of destroying them? Checking them out to researchers for no-consent research?

  • Fat rats

    Tue, 2010-03-02 21:05 -- John Hawks

    Daniel Cressey reports on research that points out the problem of laboratory rodent analogs for human health conditions: the mice and rats start out unhealthy:

    Mattson and his colleagues note that the standard lab practice of allowing rats and mice continuous access to food without much opportunity to exercise can cause some to balloon in weight to up to 1 kilogram. Beneficial effects of a potential drug or behaviour could simply result from its effect on the consequences of an animal's unhealthy lifestyle, they say, and studies showing that caloric restriction can extend lifespan may have to be reinterpreted. "A major reason the lifespan of rats and mice is extended by caloric restriction is they started from an unhealthy baseline," argues Mattson. He and his co-workers identify areas as diverse as immune function, cancer and neurological disorders that could be affected by the problem (emphasis added).

    I can add the little-noted fact that lab rodents have been selected for fecundity. Faster reproduction and larger litters are enabled by larger body size, rapid maturation, more milk production.

    Some of this may help make rodents a better analog for humans, at least fat American humans. But for many studies, it may be useful to replicate results on multiple species of laboratory animals, including some kept deliberately in different environments than the usual lab.

    UPDATE (2010-03-02): I've read the paper by Bronwen Martin and colleagues ("Control" laboratory rodents are metabolically morbid: Why it matters."). It's a nice piece of work, and includes a well-written introduction followed by a list of possible biases and problems for specific disease conditions including diabetes, cancer and neurological disorders.

    It occurs to me that understanding the problem isn't enough to get research labs to maintain healthier controls. Labs have a positive payoff from keeping their control animals fat and unhealthy, if that means the experimental treatment is more likely to show a difference.

    Especially at the level of "pilot" results, which go into grant applications and determine the chance of further funding to study a new intervention. The difference between a significant and insignificant result in a small pilot study isn't very much.

  • Cancer and personalized drugs

    Mon, 2010-02-22 12:58 -- John Hawks

    Amy Harmon reappears in the NY Times science page this week, with a series on the clinical trials of a targeted cancer drug ("A Roller Coaster Chase for a Cure").

    Dr. Flaherty, who has a near-photographic memory, was not accustomed to rereading. But in his campus office that morning, he scrolled through the article on his computer again to be sure he had understood. The presence of the same B-RAF mutation in so many cancers, he thought, meant it was one of the biggest genetic smoking guns yet identified in cancer. A drug that blocked the protein made by the defective gene might have enormous consequences for patients — and he knew of one that just might work.

    This is where the "rubber" of personalized medicine "hits the road", so to speak -- if we can find drugs that treat the specific mutations that cause a person's cancer, then there may be hope in other kinds of interventions targeted to a particular genotype.

  • Genetic lapidaries

    Thu, 2010-02-18 11:06 -- John Hawks

    Nature News has a short piece on yesterday's Desmond Tutu and other South African genomes: "Africa yields two full human genomes."

    Has anybody else noticed how it has become routine to print a short list of phenotypic associations whenever a new genome is published? Last week, the press about the Greenland genome emphasized mostly uninformative data about earwax type and hair form. It was all stuff you would have predicted anyway. Now, what pearls of information have come from the African genomes?

    Several of the DNA changes in the Khoisan may reflect adaptations to the rigorous life of a hunter-gatherer in the Kalahari Desert. Three of the Khoisan carry a version of the muscle-expressed ACTN3 gene linked to faster sprinting. !Gubi carries one copy of a form of the CLCNKB gene that encodes a cell-membrane channel capable of reabsorbing chloride ions in the kidney, a possible advantage in the desert. And all have a form of the taste-receptor gene TAS2R38 that would enable them to taste the bitter compound phenylthiocarbamide. This form of the gene may help hunter-gatherers to avoid toxic plants.

    The Khoisan also lack a gene variant giving protection against malaria infection by Plasmodium vivax. This could reflect their lifestyle, Schuster says: with both water and cattle scarce, the Khoisan face little threat from malaria. But as agricultural communities encroach on the Khoisan habitat, or more Khoisan take up farming, the population may find itself increasingly vulnerable to infection.

    OMG! They're PTC tasters! I'm so happy they sequenced the genome for that; those test strips really put a dent in the budget at $2.50 per hundred!

    The information is accurate, but these genotypes just aren't very interesting. We already knew that Duffy O is rare in southern Africa. That's another cheap phenotyping test. Are they under threat from vivax malaria? A little -- but that certainly won't help them when falciparum is the main threat. ACTN3 may not have been known already, but isn't surprising at all.

    I think there are two problems here. One: putting out this list of variants really misrepresents the purpose of the sequencing. Genotyping known variants is not the point of these sequences. If it were, the geneticists could have accomplished that with a $400 chip. Finding unknown variants is more worthwhile (and the number of new polymorphisms has been listed in some articles), but we don't know what phenotypic correlations a newly-discovered polymorphism may have. So, we get this catalog of known variations -- written like a little lapidary of genetic gems -- which is just window-dressing for the real science.

    Two: The point of having whole genomes or genome-wide genotypes is that they give us the opportunity to test hypotheses about systems of genes instead of individual genotypes. But for the most part, we don't know how to do that. Certainly on my end, looking for the causes of recent human evolution, we just haven't made great methodological progress on how to study the simultaneous evolution of many genes and their joint effect on human biology. Here in my lab, and elsewhere, we're trying really hard -- and that is to me the exciting part of this science. But we're far from the point where we can predict much from a genome.

    One aspect that hasn't gotten the attention it deserves: These genomes have a tremendous amount to tell us about the Pleistocene history of African populations. This is like an ancient record of thousands of genes, representing this area of the world where only a handful of ancient human fossils exist. Much more on that later.

  • National Children's Study update

    Wed, 2010-02-17 11:30 -- John Hawks

    Pam Belluck explains the hold-ups with the 7-billion-dollar National Children's Study: "Wanted: Volunteers, all pregnant."

    “This study is of the magnitude of the accelerator in CERN, or a trip to the moon — a really big science issue,” said Milton Kotelchuck, a professor at the Boston University School of Public Health and a member of the independent panel. “But if you have a flawed beginning, then you’ve got 20 years of working on a flawed study.”

    The study locations (105 counties nationwide) were determined by a political process -- they're strategically located in certain congressional districts. So all of the stuff in the article where Congresspeople are complaining about the unexpected price tag, well, put the blame where it belongs. The sampling scheme seems to me like it will create the mother of all confounding variables, unless they're lucky and none of the environmental measures vary among study counties in the same way.

    At any rate, the current problem is that they can't recruit enough babies. In at least one county, they've put themselves in the situation of having to recruit more than 30 percent of births! Imagine -- you've got to convince a third of families (somehow, the father's role in this never gets mentioned...) to let the government follow their child for 21 years.

  • Drug discovery and GWA

    Sun, 2010-02-14 11:59 -- John Hawks

    Gene Expression's p-ter makes an interesting point about weak genome-wide associations and drug development.

    Any doctor knows where I'm going with this: one of the best-selling groups of drugs in the world currently are statins, which inhibit the activity of (the gene product of) HMGCR. Of course, statins have already been invented, so this is something of a cherry-picked example, but my guess is that there are tens of additional examples like this waiting to be discovered in the wealth of genome-wide association study data. Figuring out which GWAS hits are promising drug targets will take time, effort, and a good deal of luck; in my opinion, this is the major lesson from Decode (which is not all that surprising a lesson)--drug development is really hard.

    Yes, figuring out gene functional networks is the hard part; also, how alleles may interact in unexpected ways with different genetic backgrounds.

  • Genetic testing brief

    Wed, 2010-02-03 22:47 -- John Hawks

    Data point:

    This is the time in my introductory class when I discuss genetic disorders, and I described the new Counsyl test as part of my lecture today.

    I took a quick poll -- how many of my undergraduates would be interested in getting a test that told them their carrier status for a hundred genetic disorders. More than half of them expressed interest. That just seems huge to me -- I don't think I'd have seen the same result ten or even five years ago. There's been a real change in attitude about genetic testing in the last few years as technology has gotten cheaper and has more public attention.

Pages

Subscribe to health

Neandertals

For years, I've worked on their bones. Now I'm working on their genes. Read more about the science studying these ancient people.

Denisova

From a finger bone of an ancient human came the record of a completely unexpected population. My lab is working on the science of the Denisova genome.

Acceleration

The advent of agriculture caused natural selection to speed up greatly in humans. We're uncovering some of the ways that populations have rapidly changed during the last 10,000 years.

Malapa

Just outside Johannesburg, the Malapa site is producing some of the most exciting finds in human evolution. This site is the headquarters of the Malapa Soft Tissue Project.